MCM
LABU icon

Mainstay Capital Management’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Mainstay Capital Management’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58
Closed -$107K – 250
2018
Q3 		$107K Buy
58
+28
+93% +$55K 0.07% 138
2018
Q2 		$57K Hold
30
– – 0.05% 167
2018
Q1 		$47K Buy
30
+10
+50% +$18.6K 0.04% 158
2017
Q4 		$31K Buy
+20
New +$30.6K 0.03% 189

Other funds holding LABU

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HIS
Harvest Investment Services Oakbrook Terrace, Illinois $547M AUM 64.58% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EWA
Exencial Wealth Advisors Oklahoma City, Oklahoma $3.22B AUM 20.17% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Mainstay Capital Management's LABU Position: Q4 2018 in Review

Mainstay Capital Management sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2018, closing a stake of 58 shares — an estimated $107K sold.

Mainstay Capital Management first reported a position in LABU in Q4 2017 and held it in 4 quarters. The position peaked at $107K in Q3 2018. 30 funds tracked by Wall St. Rank hold LABU as of Q4 2018.

  • Mainstay Capital Management reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 58 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2018, an estimated $107K.
  • Mainstay Capital Management first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2017 and held it in 4 quarters.
  • Mainstay Capital Management's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $107K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.